MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 84 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 1.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $451,959 | +15.7% | 56,144 | +56.1% | 0.00% | – |
| Q2 2023 | $390,667 | -33.2% | 35,973 | -57.6% | 0.00% | – |
| Q1 2023 | $584,789 | +93.7% | 84,752 | +11.8% | 0.00% | – |
| Q4 2022 | $301,827 | -52.9% | 75,836 | -21.3% | 0.00% | – |
| Q3 2022 | $641,000 | +37.8% | 96,375 | +0.2% | 0.00% | – |
| Q2 2022 | $465,000 | +46.7% | 96,197 | +183.5% | 0.00% | – |
| Q1 2022 | $317,000 | -46.9% | 33,937 | -32.4% | 0.00% | – |
| Q4 2021 | $597,000 | +63.1% | 50,214 | +56.3% | 0.00% | – |
| Q3 2021 | $366,000 | -33.5% | 32,118 | +4.8% | 0.00% | – |
| Q2 2021 | $550,000 | +69.2% | 30,651 | +45.9% | 0.00% | – |
| Q1 2021 | $325,000 | +29.0% | 21,009 | +2.0% | 0.00% | – |
| Q4 2020 | $252,000 | +38.5% | 20,597 | +45.6% | 0.00% | – |
| Q3 2020 | $182,000 | – | 14,142 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |